1. Home
  2. CBAT vs IGMS Comparison

CBAT vs IGMS Comparison

Compare CBAT & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBAT
  • IGMS
  • Stock Information
  • Founded
  • CBAT 1999
  • IGMS 1993
  • Country
  • CBAT China
  • IGMS United States
  • Employees
  • CBAT N/A
  • IGMS N/A
  • Industry
  • CBAT Industrial Machinery/Components
  • IGMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CBAT Miscellaneous
  • IGMS Health Care
  • Exchange
  • CBAT Nasdaq
  • IGMS Nasdaq
  • Market Cap
  • CBAT 90.8M
  • IGMS 82.1M
  • IPO Year
  • CBAT N/A
  • IGMS 2019
  • Fundamental
  • Price
  • CBAT $1.21
  • IGMS $1.21
  • Analyst Decision
  • CBAT
  • IGMS Hold
  • Analyst Count
  • CBAT 0
  • IGMS 8
  • Target Price
  • CBAT N/A
  • IGMS $6.00
  • AVG Volume (30 Days)
  • CBAT 294.1K
  • IGMS 210.0K
  • Earning Date
  • CBAT 08-08-2025
  • IGMS 05-13-2025
  • Dividend Yield
  • CBAT N/A
  • IGMS N/A
  • EPS Growth
  • CBAT N/A
  • IGMS N/A
  • EPS
  • CBAT 0.00
  • IGMS N/A
  • Revenue
  • CBAT $152,731,078.00
  • IGMS $2,681,000.00
  • Revenue This Year
  • CBAT $28.79
  • IGMS $134.30
  • Revenue Next Year
  • CBAT $36.77
  • IGMS $27.19
  • P/E Ratio
  • CBAT $13,555.56
  • IGMS N/A
  • Revenue Growth
  • CBAT N/A
  • IGMS 27.36
  • 52 Week Low
  • CBAT $0.57
  • IGMS $0.92
  • 52 Week High
  • CBAT $1.75
  • IGMS $22.50
  • Technical
  • Relative Strength Index (RSI)
  • CBAT 76.57
  • IGMS 46.10
  • Support Level
  • CBAT $0.83
  • IGMS $1.21
  • Resistance Level
  • CBAT $1.24
  • IGMS $1.40
  • Average True Range (ATR)
  • CBAT 0.07
  • IGMS 0.08
  • MACD
  • CBAT 0.02
  • IGMS -0.00
  • Stochastic Oscillator
  • CBAT 92.50
  • IGMS 8.70

About CBAT CBAK Energy Technology Inc.

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.

About IGMS IGM Biosciences Inc.

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Share on Social Networks: